IMVT · Immunovant, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-08 | Stout Jay S |
Chief Technology Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
105 |
| 2026-07-08 | Stout Jay S |
Chief Technology Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
1,399 |
| 2026-07-08 | Gloria Melanie |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
106 |
| 2026-07-08 | Stout Jay S |
Chief Technology Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
77 |
| 2026-07-08 | Van Tuyl Christopher |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
63 |
| 2026-07-08 | Gloria Melanie |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
1,930 |
| 2026-07-08 | Van Tuyl Christopher |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
1,143 |
| 2026-07-08 | Stout Jay S |
Chief Technology Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
1,906 |
| 2026-07-02 | Venker Eric |
President & Immunovant CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
Common Stock
|
3,092 |
| 2026-07-01 | Venker Eric |
President & Immunovant CEO |
Convert↑
Filing footnotes — Common Stock (Direct)
On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. |
Common Stock
|
92,188 |
| 2026-07-01 | Venker Eric |
President & Immunovant CEO |
Other↓
Filing footnotes — Common Stock (Direct)
On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. |
Common Stock
|
86,629 |
| 2026-07-01 | Venker Eric |
President & Immunovant CEO |
Convert↓
Filing footnotes — Capped Value Appreciation Rights (Direct)
On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share. |
Capped Value Appreciation Rights
|
92,188 |
| 2026-06-26 | Pande Atul |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. |
Common Stock
|
1,500 |
| 2026-06-26 | Pande Atul |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. |
Common Stock
|
1,500 |
| 2026-06-26 | Gloria Melanie |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 - $38.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
14,748 |
| 2026-06-26 | Girao Tiago |
Chief Financial Officer |
Convert↑
|
Common Stock
|
10,000 |
| 2026-06-26 | Stout Jay S |
Chief Technology Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.76 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
6,723 |
| 2026-06-26 | Girao Tiago |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 - $38.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
10,000 |
| 2026-06-26 | Stout Jay S |
Chief Technology Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.74 - $38.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
33,277 |
| 2026-06-26 | Van Tuyl Christopher |
Chief Legal Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
Award of stock options to purchase Common Shares with a grant date of April 1, 2025. The shares underlying the option vest as to 25% on April 1, 2026, with the remainder vesting in 36 successive substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date. |
Stock Option (right to buy)
|
17,824 |
| 2026-06-26 | Van Tuyl Christopher |
Chief Legal Officer |
Convert↑
|
Common Stock
|
17,824 |
| 2026-06-26 | Gloria Melanie |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.78 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
2,966 |
| 2026-06-26 | Van Tuyl Christopher |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 - $38.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
14,982 |
| 2026-06-26 | Girao Tiago |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
Award of stock options to purchase Common Shares with a grant date of May 1, 2025. The shares underlying the option vest as to 25% on April 21, 2026, with the remainder vesting in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date. |
Stock Option (right to buy)
|
10,000 |
| 2026-06-26 | Pande Atul |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Reflects an award of stock options to purchase Common Shares that is fully vested. |
Stock Option (right to buy)
|
1,500 |
| 2026-06-26 | Van Tuyl Christopher |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 - $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
2,842 |
| 2026-06-18 | Van Tuyl Christopher |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on June 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
Common Stock
|
2,634 |
| 2026-06-15 | Pande Atul |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. |
Common Stock
|
1,500 |
| 2026-06-15 | Pande Atul |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Reflects an award of stock options to purchase Common Shares that is fully vested. The Form 4 filed on May 20, 2026 inadvertently disclosed the total of all remaining options held by the Reporting Person following the reported transaction in this specific option. This total correctly reflects only the remaining options for the specific option. |
Stock Option (right to buy)
|
1,500 |
| 2026-06-15 | Pande Atul |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. |
Common Stock
|
1,500 |
| 2026-05-28 | Fromkin Andrew J. |
Director |
Convert↑
|
Common Stock
|
31,668 |
| 2026-05-28 | Fromkin Andrew J. |
Director |
Convert↑
|
Common Stock
|
77,181 |
| 2026-05-28 | Fromkin Andrew J. |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
Reflects an award of stock options to purchase Common Shares that is fully vested. |
Stock Option (right to buy)
|
31,668 |
| 2026-05-28 | Fromkin Andrew J. |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
Reflects an award of stock options to purchase Common Shares that is fully vested. |
Stock Option (right to buy)
|
16,260 |
| 2026-05-28 | Fromkin Andrew J. |
Director |
Convert↑
|
Common Stock
|
71,492 |
| 2026-05-28 | Fromkin Andrew J. |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
Reflects an award of stock options to purchase Common Shares that is fully vested. |
Stock Option (right to buy)
|
77,181 |
| 2026-05-28 | Fromkin Andrew J. |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 - $33.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
210,468 |
| 2026-05-28 | Fromkin Andrew J. |
Director |
Convert↑
|
Common Stock
|
16,260 |
| 2026-05-28 | Fromkin Andrew J. |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
Reflects an award of stock options to purchase Common Shares that is fully vested. |
Stock Option (right to buy)
|
71,492 |
| 2026-05-28 | Fromkin Andrew J. |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 - $33.035 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
11,483 |
| 2026-05-20 | Gloria Melanie |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on May 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.32 - $31.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
249 |
| 2026-05-20 | Gloria Melanie |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on May 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.55 - $32.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
1,168 |
| 2026-05-20 | Gloria Melanie |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On November 18, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on May 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.55 - $33.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
1,698 |
| 2026-05-20 | Pande Atul |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. |
Common Stock
|
6,000 |
| 2026-05-20 | Pande Atul |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. |
Common Stock
|
6,000 |
| 2026-05-20 | Pande Atul |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Reflects an award of stock options to purchase Common Shares that is fully vested. |
Stock Option (right to buy)
|
6,000 |
| 2026-05-01 | Susman Robert Graham |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 - $27.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
2,502 |
| 2026-04-23 | Stout Jay S |
Chief Technology Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on April 17, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.23 - $30.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
2,754 |
| 2026-04-23 | Girao Tiago |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On May 1, 2025, the holder was granted 208,388 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on May 5, 2025, of which 52,097 of these RSUs vested on April 21, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.23 - $30.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
25,760 |
| 2026-04-08 | Van Tuyl Christopher |
Chief Legal Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 12,696 of these RSUs vested on April 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Common Stock
|
5,165 |